G1 Therapeutics, Inc.

NC

UEI
L72RA25Z7LK3
CAGE
59AR1
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
700 Park Offices Dr #200, Research Triangle, NC 27709, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract vehicles

Grant awards

Award Agency Obligated Awarded
Development of GZ38-1, a novel protectant of chemotherapy-induced myelosuppressio R44CA174074 National Cancer Institute (NIH) $1,147,510
Development of CDK4/6 inhibitors as novel renal protectants R43DK095640 National Institutes of Health $159,836
Organismal radioprotection through pharmacological quiescence R44AI084284 National Institutes of Health $3,000,000
Organismal radioprotection through pharmacological quiescence R43AI084284 National Institutes of Health $692,326

Quick answers

Is G1 Therapeutics, Inc. registered in SAM.gov?

Yes. G1 Therapeutics, Inc.'s SAM.gov registration is active through November 12, 2026.

Which contract vehicles does G1 Therapeutics, Inc. hold?

G1 Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

What is G1 Therapeutics, Inc.'s most recent federal award?

G1 Therapeutics, Inc.'s most recent federal grant award is Development of GZ38-1, a novel protectant of chemotherapy-induced myelosuppressio (R44CA174074), from National Cancer Institute (NIH), on May 16, 2013.

On GovTribe

See G1 Therapeutics, Inc.'s full federal record

  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login